Skip to main
CYRX
CYRX logo

CryoPort (CYRX) Stock Forecast & Price Target

CryoPort (CYRX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

CryoPort Inc. reported a total revenue of $44 million, reflecting a 15% year-over-year organic growth rate, which shows a slight improvement from the previous quarter's 14% growth. The company's strong performance is supported by an increasing number of gene therapy programs in various stages of development, particularly in oncology and rare diseases, indicating a robust pipeline in the biopharma sector. With the expected rise in both commercial revenue and clinical trial activity driven by the growing acceptance of cell and gene therapies, the outlook for CryoPort remains positive.

Bears say

CryoPort Inc. is experiencing a slowdown in demand for its Life Sciences Services, with revenue growth decreasing from 21% to 16% quarter-over-quarter, despite exceeding consensus expectations. Additionally, the company's adjusted EBITDA margin remains negative at (1.5%), although it improved year-over-year, it fell short of the consensus estimate of (1.0%). The outlook is further complicated by expectations of reduced revenue growth stemming from fewer-than-anticipated cell and gene therapy approvals, alongside a decline in demand for critical equipment, leading to lowered earnings per share projections for 2026.

CryoPort (CYRX) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CryoPort (CYRX) Forecast

Analysts have given CryoPort (CYRX) a Buy based on their latest research and market trends.

According to 9 analysts, CryoPort (CYRX) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CryoPort (CYRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.